| Literature DB >> 35433761 |
Bingtian Dong1, Yuping Chen2, Guorong Lyu1,3, Yongjian Chen1, Ran Qin4.
Abstract
Background: Measurement of hepatic venous pressure gradients is the gold standard for assessing portal hypertension (PH) but is invasive with potential complications. We aimed to assess the performance in liver and spleen stiffness measurement (LSM and SSM, respectively) by two-dimensional shear wave elastography (2D-SWE) and composite scores including liver stiffness-spleen diameter to platelet ratio score (LSPS), platelet (PLT) count/spleen diameter ratio (PSR), aspartate aminotransferase (AST)/alanine aminotransferase ratio (AAR), and AST-to-PLT ratio index (APRI) for diagnosing PH in nonalcoholic fatty liver disease (NAFLD) rat models.Entities:
Keywords: diagnosis; nonalcoholic fatty liver disease; noninvasive method; portal hypertension; two-dimensional shear wave elastography
Year: 2022 PMID: 35433761 PMCID: PMC9008888 DOI: 10.3389/fmed.2022.844558
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Two-dimensional shear wave elastography (2D-SWE) measurement of the (A) liver and (B) spleen, and (C) image of liver section stained with hematoxylin and eosin in a rat model with NAFLD. The mean LSM and SSM were 11.3 ± 0.4 and 15.6 ± 0.7 kPa, respectively. The image of liver section revealing fibrosis stage F4 (cirrhosis). LSM, liver stiffness measurement; NAFLD, nonalcoholic fatty liver disease; SSM, spleen stiffness measurement.
Biological, morphological, and elastography characteristics of controls and rats with NAFLD.
|
|
|
|
|
|---|---|---|---|
|
| 15 | 51 | |
| Platelet count, 109/L | 787.5 ± 32.18 | 828.9 ± 23.41 | 0.419 |
| Red cell distribution width (%) | 14.7 ± 0.12 | 15.8 ± 0.16 | 0.041 |
| ALT, IU/L | 60.7 ± 2.58 | 145.5 ± 15.73 | 0.009 |
| AST, IU/L | 208.5 ± 12.34 | 245.8 ± 18.82 | 0.333 |
| GGT, IU/L | 0.90 ± 0.18 | 1.91 ± 0.48 | 0.441 |
| Spleen diameter, cm | 3.58 ± 0.01 | 3.81 ± 0.03 | <0.001 |
| PVP measurement, mmHg | 4.80 ± 0.03 | 12.03 ± 0.28 | <0.001 |
| LSM, kPa | 7.1 (6.6–7.4) | 9.1 (7.9–11.0) | <0.001 |
| SSM, kPa | 12.8 (12.3–13.3) | 15.7 (14.1–17.9) | <0.001 |
Data are mean ± standard deviation or median (interquartile range), or number of rats, when appropriate.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; LSM, liver stiffness measurement; NAFLD, nonalcoholic fatty liver disease; PVP, portal venous pressure; SSM, spleen stiffness measurement.
Technical success and reliability of LSM and SSM by 2D-SWE in rats with NAFLD.
|
|
|
| |
|---|---|---|---|
|
|
| ||
| LSM | 64 (100%) | 0 | 0 |
| SSM | 51 (79.7%) | 8 (12.5%) | 5 (7.8%) |
Data are expressed as number of rats, with percentages in parentheses.
P < 0001; the success rate of LSM by 2D-SWE was higher than that of SSM.
LSM, liver stiffness measurement; NAFLD, nonalcoholic fatty liver disease; SSM, spleen stiffness measurement; 2D-SWE, two-dimensional shear wave elastography.
Figure 2Scatterplots showing correlations between (A) LSM, (B) SSM, and portal venous pressure, as well as (C) LSM with SSM in rat models with NAFLD. LSM, liver stiffness measurement; NAFLD, nonalcoholic fatty liver disease; PVP, portal venous pressure; SSM, spleen stiffness measurement.
Figure 3Distribution of (A) LSM and (B) SSM in rats with and those without PH, as well as distribution of (C) LSM and (D) SSM in NAFLD rats with and those without CSPH (a portal venous pressure of 10 mmHg or higher). LSM and SSM were significantly higher in the rats with PH than in the rats without PH. Similarly, LSM and SSM were significantly higher in the rats with NAFLD and CSPH than in those with NAFLD but without CSPH. CSPH, clinically significant portal hypertension; LSM, liver stiffness measurement; PH, portal hypertension; SSM, spleen stiffness measurement.
Predictive value of noninvasive methods and combined models for assessing portal venous pressure.
|
|
| |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| LSM, kPa | 7.7 | 0.906 (0.841–0.970) | 79.7 (67.8–88.7) | 100 (78.2–100) | 100 | 53.6 |
| SSM, kPa | 13.4 | 0.870 (0.776–0.964) | 86.3 (73.7–94.3) | 80.0 (51.9–95.7) | 93.6 | 63.2 |
| LSPS | 0.04 | 0.793 (0.688–0.898) | 73.4 (60.9–83.7) | 73.3 (44.9–92.2) | 92.2 | 39.3 |
| PSR | 197.8 | 0.520 (0.366–0.673) | 37.5 (25.7–50.5) | 86.7 (59.5–98.3) | 92.3 | 24.5 |
| AAR | 3.18 | 0.668 (0.550–0.772) | 76.7 (64.0–86.6) | 60.0 (32.3–83.7) | 88.5 | 39.1 |
| APRI | 0.23 | 0.533 (0.414–0.649) | 50.0 (36.8–63.2) | 73.3 (44.9–92.2) | 88.2 | 26.8 |
| Combined model 1 | 0.73 | 0.923 (0.858–0.988) | 86.3 (73.7–94.3) | 100 (78.2–100) | 100 | 58.2 |
| Combined model 2 | 0.74 | 0.913 (0.851–0.974) | 84.4 (73.1–92.2) | 100 (78.2–100) | 100 | 60.0 |
| Combined model 3 | 0.65 | 0.872 (0.779–0.965) | 88.2 (76.1–95.6) | 80.0 (51.9–95.7) | 93.8 | 66.6 |
| Combined model 4 | 0.71 | 0.923 (0.858–0.988) | 84.3 (71.4–92.3) | 100 (78.2–100) | 100 | 65.2 |
combined model 1 represents LSM and SSM combined model;
combined model 2 represents LSM and platelet count combined model;
combined model 3 represents SSM and platelet count combined model; ‡, combined model 4 represents LSM and SSM, platelet count combined model.
AAR, aspartate aminotransferase/alanine aminotransferase ratio; APRI, aspartate aminotransferase-to-platelet count ratio index; AUC, area under the receiver operating characteristic curve; CI, confidence interval; LSM, liver stiffness measurement; LSPS, liver stiffness-spleen diameter to platelet ratio score; NPV, negative predictive value; PPV, positive predictive value; PSR, platelet count/spleen diameter ratio; SSM, spleen stiffness measurement.
Figure 4Receiver operating characteristic curves of (A) LSM, (B) SSM, and (C–F) the four combined models for predicting portal venous pressure. AUC, area under the receiver operating characteristic curve; LSM, liver stiffness measurement; PH, portal hypertension; PLT, platelet count; SSM, spleen stiffness measurement.